Cabozantinib and ifosfamide for relapsed sarcomas
Treatments studied
Part of Cancer clinical trials.
This study tests a combination of two drugs, cabozantinib and ifosfamide, for sarcomas that have come back or not responded to treatment. The goal is to see if this combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a sarcoma (a type of bone or soft tissue cancer) that has come back or not responded to past treatment.
- You are between 5 and 40 years old and your body surface area is more than 0.35 square meters.
- You are able to swallow pills whole.
- You have not taken cabozantinib before and had your cancer get worse while on it.
- You have not had a high dose of ifosfamide (more than 10 grams per square meter of body surface area) in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether combining pembrolizumab and cabozantinib can control advanced sarcoma that can’t be removed by surgery and has grown or returned after standard treatment. It may help shrink tumors and improve outcomes in adults who have limited treatment options left.
This trial tests a combination of three drugs (liposomal irinotecan, temozolomide, and fluzoparib) for people with Ewing sarcoma that has spread or come back after first treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial combines four targeted drugs (gefitinib, trametinib, disulfiram, sunitinib) with standard chemotherapy to treat osteosarcoma that has spread or come back. The goal is to see if this drug mix helps shrink tumors or keep them from growing.
This trial tests whether a new drug (called cabozantinib) can help keep osteosarcoma from coming back after initial treatment. It is for people who have completed their first round of therapy and have no sign of active cancer or only stable disease.
This study tests a combination of two drugs, MM-398 and cyclophosphamide, for children and young adults whose cancer has come back or not responded to earlier treatment. The goal is to find the best dose and see how well it works against certain tumor types.
This trial tests a drug called eflornithine (DFMO) for people with Ewing sarcoma or osteosarcoma that has come back or spread. The goal is to see if DFMO can help control the cancer after standard treatment.
Hear when a new Ewing Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.